Multinational phase 2 trial of nivolumab with or without nivolumab-ipilimumab boost for metastatic renal cell carcinoma
Prof. Marc-Oliver Grimm
The multinational phase 2 TITAN-RCC trial found that among patients with previously untreated intermediate- or poor-risk metatatic renal cell carcinoma, nivolumab monotherapy with or without nivolumab-ipilimumab boost significantly improved the objective response rate compared with that reported for nivolumab monotherapy in the CheckMate-025 trial. However, overall efficacy seemed inferior when compared with upfront nivolumab plus ipilimumab. For second-line treatment, nivolumab plus ipilimumab could be a rescue strategy on progression with nivolumab monotherapy.
